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Background. Necrotizing fasciitis (NF) retains a very high mortality rate despite prompt and adequate antibiotic treatment and 
surgical debridement. Necrotizing fasciitis has recently been associated with Streptococcus dysgalactiae subspecies equisimilis (SDSE).
Methods. We investigated the causes of a very severe clinical manifestation of SDSE-NF by assessing both host and pathogen 
factors.
Results. We found a lack of streptokinase-function blocking antibodies in the patient resulting in increased streptokinase-me-
diated fibrinolysis and bacterial spread. At the same time, the clinical SDSE isolate produced very high levels of streptokinase. 
Exogenous immunoglobulin Gs (ex-IgGs) efficiently blocked streptokinase-mediated fibrinolysis in vitro, indicating a protective role 
against the action of streptokinase. In vivo, SDSE infection severity was also attenuated by ex-IgGs in a NF mouse model.
Conclusions. These findings illustrate for the first time that the lack of specific antibodies against streptococcal virulence factors, 
such as streptokinase, may contribute to NF disease severity. This can be counteracted by ex-IgGs.
Keywords. bacterial spreading; fibrinolysis; necrotizing fasciitis; pooled human immunoglobulin; Streptococcus dysgalactiae 
subspecies equisimilis; streptokinase.
 
Streptococcus dysgalactiae subspecies equisimilis (SDSE or 
group C/G Streptococcus) causes a broad spectrum of human 
diseases ranging from superficial to invasive infections such 
as necrotizing fasciitis (NF) and streptococcal toxic shock-like 
syndrome (STSS) [1], commonly associated with Streptococcus 
pyogenes (aka group A Streptococcus or GAS). However, recent 
studies indicate that SDSE has emerged among the bacterial 
strains isolated from severe infections [2, 3], such that a better 
understanding of the interplay between molecular pathogenesis 
of SDSE virulence and host defence strategies is essential.
Necrotizing fasciitis is the most feared severe invasive 
infection caused by SDSE. The lethality can be as high as 
33% [4]. State-of-the-art NF therapy currently consists of 
surgical debridement, administration of cell-wall-active [5], 
and protein-synthesis-inhibiting antibiotics [6]. Exogenous 
commercially available pooled human intravenous immuno-
globulin (ex-IgGs or IVIG) may be administered in addition, 
albeit evidence from sufficiently powered clinical trials is lack-
ing [7]. A comparative observational study recently showed that 
ex-IgGs infusion is beneficial in patients with GAS STSS [8], 
suggesting that antibody-mediated blocking of STSS-associated 
virulence factors (VFs) could prove to be beneficial.
Streptococcus dysgalactiae subspecies equisimilis-associated 
NF is an emerging problem with clinical features reminiscent of 
GAS-associated NF [1]. In view of these similarities, the reper-
toire of contributing VFs expressed by SDSE might overlap with 
those of GAS. In GAS, VFs contributing to invasive infection 
include the hyaluronic acid (HA) capsule, the pore-forming 
toxin streptolysin O (SLO), the fibrin-degrading enzyme strep-
tokinase, the cysteine protease SpeB, extracellular deoxyribonu-
cleases (DNases), and the interleukin (IL)-8 cleaving S pyogenes 
cell envelope proteinase (SpyCEP). Many of these VFs have 
been directly linked to disease severity [9–11], whereas VFs in 
SDSE have not been evaluated in depth so far.
In this study, we investigated the interplay between the host 
and the SDSE strain causing a fulminant and lethal NF, aim-
ing to elucidate the pathophysiology of the disease and further 
optimize treatment. Examination of host factors revealed an 
absence of streptokinase-blocking antibodies in the patient’s 
plasma, potentially resulting in facilitated bacterial escape due 
to the lack of containment within the host’s fibrin barriers. At 
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the same time, the SDSE NF-isolate was characterized by a 
highly elevated streptokinase activity causing blood clot lysis 
and consequent bacterial spreading.
METHODS
Case
A 38-year-old morbidly obese woman with a history of drug 
and alcohol abuse was brought to the emergency room of the 
University Hospital of Zurich, Switzerland, because of confusion. 
On arrival, she rapidly developed septic shock, with the Glasgow 
coma scale falling from 14 to 8, and progressive cardiopulmonary 
failure requiring mechanical ventilation, volume, and vasopressor 
therapy. Her legs were covered with psoriatic lesions, bullae, and 
necrotic areas. Suspected NF was confirmed by magnetic reso-
nance tomography and supported by massively increased leuco-
cyte and neutrophil counts (41.57 grams/L and 39.84 grams/L, 
respectively) and elevated C-reactive protein (225 mg/L). Initial 
empiric antibiotic therapy included piperacillin/tazobactam and 
clindamycin and was complemented by ex-IgGs and extensive 
surgical debridement of the necrotic subcutaneous tissue of pelvis, 
thighs, lower legs, and feet. Necrosis progressed requiring sub-
sequent debridement of the abdominal wall. Despite all efforts, 
sepsis advanced and she died on day 12 in multiorgan failure. In 
the necrotic tissue, masses of Gram-positive cocci in chains were 
observed and identified as SDSE. This SDSE NF-isolate was used 
for subsequent in vitro and in vivo analyses.
Strains and Growth Conditions
The SDSE NF-isolate was isolated from the NF patient described 
above and compared with the insertional mutant SDSE:skg 
obtained using the insertion plasmid pVE6007-ska-int [12], as 
previously described [13]. The invasive GAS serotype M1T1 strain 
5448, isolated from a NF patient (GAS wild-type [WT] or GAS 
NF-isolate) [14], was used together with its derivative animal-pas-
saged strain (GAS AP), overexpressing VFs [12, 15], and the de-
letion mutants GAS ΔspeB [16] and GAS ΔcepA [10]. All strains 
were grown in Todd Hewitt Broth (BD) supplemented with 2% 
yeast extract (THY) at 37°C under static conditions. The SDSE:skg 
was grown with 5  μg/mL chloramphenicol. Overnight culture 
supernatants (16–20 hours) were harvested by centrifugation and 
filter-sterilized through a 0.22-μm filter (Merck Millipore Ltd.).
Histology and Staining
Tissues were fixed with 10% buffered formalin. Fixed tissue 
slides (2 µm) were stained with hematoxylin and eosin, Brown 
Brenn, or acid Fuchsine-Orange G. Whole slide scanning and 
photomicrography were performed using a NanoZoomer 2.0-
HT digital slide Scanner (Hamamatsu).
Virulence Factors Activity Assessment
Activity of the VFs SLO [17], SpeB [18, 19], Sda1 [11], SpyCEP 
[10], and hyaluronic acid content [20] were assessed as pre-
viously described. Streptokinase activity was quantified by 
assessing the fibrinolytic capacity of the strains’ supernatants. 
Twenty microliters of bacterial supernatant were added to 
100  µL plasminogen (20  µg/mL; Haematologic Technlogies) 
in Tris-buffered saline, pH 7.5. After a 15-minute incubation 
at 37°C, the generation of plasmin was quantified in a kinetic 
colorimetric assay (30 minutes, 5-minute intervals, absorb-
ance at 405 nm) with a spectrophotometer (Molecular Devices) 
using 2.5 mM Spectrozyme (American Diagnostica Gmbh) as 
substrate.
Strepokinase Sequence Analysis
The streptokinase gene of various clinical SDSE isolates as well 
as of the GAS serotype M1T1 strain 5448 amplified by poly-
merase chain reaction was sequenced (Microsynth), and se-
quence alignment and phylogenetic analysis was performed 
using MegAlign Pro version 14.1.0 (DNASTAR). A  panel of 
streptokinase GAS sequences was obtained from the National 
Center for Biotechnology Information for comparison.
emm-Typing
emm-typing of the SDSE NF-isolate was carried out accord-
ing to the guidelines of the Centers for Disease Control and 
Prevention (https://www2a.cdc.gov/ncidod/biotech/strepblast.
asp). The SDSE NF-isolate was identified as stG6.0 type.
Clotting Assay
Freshly drawn blood was collected in Vacutainer citrate tubes 
(BD Diagnostics). Platelet-poor-plasma (PPP) was obtained 
by centrifuging whole blood at 1500 g for 15 minutes, followed 
by 10 000 g for 10 minutes to remove platelets. When needed, 
PPP was stripped of the donor’s endogenous immunoglobulins 
(en-IgGs) using Protein-G Gravitrap columns (GE Healthcare). 
Plasma from 5 healthy human volunteers was screened, and one 
found displaying susceptibility towards fibrinolysis by SDSE 
NF-isolate supernatants. To obtain a larger stock of susceptible 
plasma, consecutive samples of fresh frozen PPP were screened, 
and the 7th sample was susceptible towards fibrinolysis and used 
as standard. Clotting assays where performed on a RoTeg ana-
lyzer (Axonlab) according to the manufacturer’s instructions. 
Seventy microliters of bacterial supernatant were incubated 
with either 270 µL blood or 200 µL PPP supplemented with 70 
µL fibrinogen (4 mg/mL Haemocomplettan). When indicated, 
ex-IgGs (11.5 mg/mL Privigen) were preincubated for 20 min-
utes with bacterial supernatants. To assess clot lysis caused by 
recombinant streptokinase (rSkg) and to assess the blocking 
effect of ex-IgGs, PPP was mixed with fibrinogen and purified 
streptokinase (3 U/mL; Sigma) in the presence or absence of 
10 mg/mL ex-IgGs. To assess the specificity of streptokinase 
activity blockage by ex-IgGs, PPP was mixed with fibrinogen. 
Recombinant streptokinase (1 U/mL) or SDSE NF-isolate’s su-
pernatant were added to the mixture in the presence or absence 
of 10 mg/mL of a commercial streptokinase-blocking antibody 
(Abcam ab35168).
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Murine Infection Model
The SDSE NF-isolate and SDSE:skg were injected subcutane-
ously (1.5 × 106 colony-forming units) into the shaved flanks of 
8- to 10-week-old female C57BL/6 WT mice (Janvier). Bacteria 
were prepared for injection as previously described [21]. The 
ex-IgG mice group was treated with intraperitoneal injections 
of 10 mg of ex-IgGs on day 1 and 5 mg of ex-IgGs on day 2 and 3 
postinfection. Mice were sacrificed on day 3 postinfection, and 
skin samples were collected for enumeration of bacteria [10].
Statistics
Data analysis and presentation were performed using GraphPad 
software. A 2-sample, 2-tailed, homoscedastic t test was used to 
calculate the indicated P values.
Study Approval
Collections of patient and healthy volunteers’ samples complied 
with the current version of the Declaration of Helsinki. The na-
tional legal and regulatory requirements and sample collection 
were approved by the Canton Ethics Committee (Kantonale 
Ethikkommission Zurich, Switzerland, KEK-ZH-Nr. BASEC 
2016-00145 and 2010-0126). For animal studies, the protocol 
ZH251/14 was approved by the Institutional Animal Care and 
Use Committee of the University of Zurich.
RESULTS
Histopathological Findings in the Patient
Histopathologic assessment of the debrided necrotic tissue of 
the NF patient revealed tissue necrosis and fascial acute neutro-
philic necrotizing inflammation (Supplementary Figure S1A) 
as well as the presence of many chain-forming, Gram-positive, 
partially intracellular cocci (Supplementary Figure S1B) and 
a striking paucity of extravascular fibrin barriers usually sur-
rounding acute inflammation areas (Supplementary Figure 
S1C). Furthermore, numerous intravascular fibrin thrombi 
were present outside of the main lesion (Supplementary Figure 
S1C, top left panel). The SDSE was isolated from the patient.
Individual Susceptibility to Streptococcus dysgalactiae Subspecies equi-
similis Necrotizing Fasciitis-Isolate-Mediated Fibrinolysis
Given the paucity of extravascular fibrin barriers containing 
inflamed areas detected in the patient, we examined clotting 
parameters of the patient and healthy volunteers. Blood from 
most human donors clotted normally even when spiked with 
supernatants produced by the SDSE NF-isolate (Figure 1A and 
C). However, bacterial supernatants induced very efficient clot 
lysis in a specific subset of donors (Figure 1B and D), similarly 
to the susceptibility to clot lysis displayed by a sample initially 
collected from the patient. In addition to promoting clot lysis, 
SDSE NF-isolate supernatants delayed clot formation and af-
fected maximal clot firmness in susceptible blood phenotypes 
(Figure  1D), consistent with extravascular fibrin barrier re-
moval at sites of infection.
Elevated Streptokinase Activity in the Streptococcus dysgalactiae 
Subspecies equisimilis Necrotizing Fasciitis-Isolate
In a second step, we examined the SDSE NF-isolate for the ac-
tivity of VFs known to contribute to the pathogenesis of NF 
caused by the related pathogen GAS, to elucidate their role 
in the pathogenesis of this particular NF case. The activity of 
SLO displayed by the SDSE NF-isolate was comparable to that 
displayed by the GAS NF-isolate, but it was lower than that 
expressed by its more virulent version GAS AP (Supplementary 
Figure S2A). No SpeB, DNase, or SpyCEP activities was detect-
able in the SDSE NF-isolate (Supplementary Figure S2B, C, and 
D). Hyaluronic acid capsule content was also much lower com-
pared with the GAS NF-isolate (Supplementary Figure S2E). 
However, the SDSE NF-isolate displayed a higher streptokinase 
activity compared with the GAS NF-isolate and its AP-derivative 
(Supplementary Figure S2F). We performed phylogenetic anal-
ysis of the streptokinase gene from this SDSE NF-isolate and 
other SDSE isolates, as well as a panel of GAS streptokinase 
genes. All SDSE streptokinase genes clustered together, sug-
gesting that there was not a unique phylogenetic origin for the 
streptokinase gene in this SDSE NF-isolate (Supplementary 
Figure S3). This SDSE streptokinase cluster was more closely 
related to streptokinase from M49 GAS NZ131 (Cluster 1 strep-
tokinase) than streptokinase from other GAS isolates.
Endogenous and Exogenous Immunoglobulin Block Streptokinase-
Mediated Fibrinolysis
We hypothesized that streptokinase activity inhibition in the re-
sistant blood phenotype samples tested could be attributable to 
the presence of streptokinase-blocking antibodies. To confirm 
this hypothesis, en-IgGs were depleted from PPP of individuals 
resistant to streptokinase-mediated clot lysis. After removal of 
en-IgGs, addition of SDSE NF-isolate supernatants lead to clot 
lysis (Figure 2A and C), suggesting that endogenous streptoki-
nase-blocking antibodies were removed. Likewise, addition of 
pooled human immunoglobulin (ex-IgGs) to PPP derived from 
streptokinase-susceptible blood resulted in inhibition of clot 
lysis (Figure 2B and D), indicating that streptokinase-blocking 
antibodies had been lacking in these susceptible individuals.
Streptokinase Is Necessary and Sufficient to Cause Fibrinolysis in 
Susceptible Individuals
To test whether SDSE streptokinase activity was necessary 
to cause fibrinolysis in susceptible blood samples, we gen-
erated the SDSE:skg strain, lacking streptokinase activity 
(Supplementary Figure S4A and B). Consistent with strepto-
kinase requirement, fibrin clots were lysed by supernatants 
of the SDSE NF-isolate but not of SDSE:skg (Figure  3A and 
B). To test whether streptokinase was sufficient to induce clot 
lysis, exogenous rSkg was added to susceptible and nonsus-
ceptible PPP. Again, rSkg lysed clots in susceptible individuals, 
and clot lysis was blocked by addition of ex-IgGs (Figure 3C 
and D) or a commercial streptokinase-blocking antibody 
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(Supplementary Figure S5A and B). Blood clot lysis was also 
blocked by a commercial streptokinase-blocking antibody 
(Supplementary Figure S5C and D), indicating that streptoki-
nase is necessary and sufficient to mediate clot lysis in suscep-
tible plasma samples.
Blockage of the Virulence Factor Streptokinase by Ex-Immunoglobulin Gs 
in a Murine Necrotizing Fasciitis Model
To test whether treatment of SDSE NF with ex-IgGs improves 
clinical outcome by blocking streptokinase activity and contain-
ing SDSE infections, mice were infected subcutaneously with 
the SDSE NF-isolate and treated or not with ex-IgGs. Three days 
postinfection, mice were euthanized, lesion size at the site of 
infection was recorded, and bacterial loads in the infected skin 
were quantified. Although the bacterial count in the skins was 
identical, a significantly reduced lesion size was observed in the 
ex-IgGs-treated group (Figure 4A), underlining the importance 
of antibody-mediated interference with VFs in bacterial infec-
tions and consistent with host fibrin deposit containment of 
bacterial spread.
In a second step, we tested the contribution of streptokinase 
to SDSE virulence in vivo. Mice were infected subcutaneously 
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Figure 1. Individual susceptibility to the Streptococcus dysgalactiae subspecies equisimilis (SDSE) necrotizing fasciitis (NF)-isolate-mediated fibrinolysis. Whole blood from 
resistant or susceptible donors was mixed with SDSE NF-isolate supernatants, and clot formation and lysis were analyzed using a roTeg analyzer. (A) Thromboelastogram 
of resistant blood phenotype. (B) Thromboelastogram of susceptible blood phenotype. (C) Clot and lysis parameters of resistant blood phenotype. Values are calculated by 
pooling the results of experiments from 4 different resistant donors. (D) Clot and lysis parameters of susceptible blood phenotype. Values are calculated by pooling the results 
of 3 independent experiments carried out on a single susceptible donor. Mean values are reported ± standard error of the mean. Significance was calculated using the paired 
t test (**, P < .01; ****, P < .001). Abbreviations: CFT, clot formation time; LI30, lysis index at 30 minutes; LI45, lysis index at 45 minutes; MCF, monocyte chemoattractant 
protein; ML, maximum lysis; n.a., infinite clot formation time for weak clots (maximum clot firmness <20 mm).
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with the SDSE NF-isolate or SDSE:skg, devoid of streptoki-
nase activity. Bacterial load was comparable for both strains 
(Figure 4B). However, in the absence of streptokinase, the lesion 
size was significantly reduced and consistent with a role of func-
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Figure 2. Endogenous and exogenous immunoglobulin (Ig) block fibrinolysis. Platelet-poor plasma from resistant or susceptible donors was mixed with Streptococcus dysga-
lactiae subspecies equisimilis (SDSE) necrotizing fasciitis (NF)-isolate supernatants, and clot formation and lysis were analyzed using a roTeg analyzer. (A) Thromboelastogram 
of resistant blood phenotype treated with SDSE supernatant before (top, en+) and after (bottom, en−) depletion of endogenous IgGs (en). (B) Thromboelastogram of suscep-
tible blood phenotype treated with SDSE supernatant before (top, ex−) and after (bottom, ex+) addition of exogenous IgGs (ex). (C) Clot formation and lysis parameters of re-
sistant blood phenotype before and after depletion of endogenous IgGs (en), with and without exogenous IgGs (ex) addition. The values were calculated by pooling the results 
of 3 independent experiments on 3 different resistant donors. (D) Clot formation and lysis parameters of susceptible blood phenotype before and after addition of exogenous 
IgGs (ex). Values were calculated by pooling the results of 3 independent experiments on a single susceptible donor. Mean values are reported ± standard error of the mean. 
Significance was calculated using the paired t test (**, P < .01; ***, P < .005). Abbreviations: CFT, clot formation time; LI30, lysis index at 30 minutes; LI45, lysis index at 45 
minutes; ML, maximum lysis; n.a., infinite clot formation time for weak clots (maximum clot firmness <20 mm).
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DISCUSSION
Focusing on the interplay between host and pathogen to under-
stand the extensive, rapidly progressive, and lethal case of NF 
caused by SDSE, we showed that the patient lacked streptoki-
nase-blocking antibodies and that the SDSE strain expressed 
very high levels of streptokinase. Using genetical and phar-
macological loss and gain of function tools, we showed that 
the presence of streptokinase was necessary and sufficient (1) 
for causing fibrinolysis in human blood ex vivo in suscepti-
ble individuals and (2) to drive virulence in vivo in a murine 
NF model. The presence of streptokinase was counteracted by 
antibodies both ex vivo and in vivo. When streptokinase-block-
ing antibodies were present, fibrinolysis was not observed in 












































































































































































Figure 3. Streptokinase is necessary and sufficient to cause fibrinolysis in susceptible individuals. Platelet-poor-plasma (PPP) from resistant or susceptible donors was 
mixed with Streptococcus dysgalactiae subspecies equisimilis (SDSE) necrotizing fasciitis (NF) isolate or SDSE:skg supernatants or with recombinant streptokinase (rSkg) in 
the presence or absence of exogenous immunoglobulin Gs (ex-IgGs). Clot formation and lysis were analyzed using a roTeg analyzer. (A) Thromboelastogram of susceptible 
blood-derived PPP in the presence (SDSE, top left panel) or absence (SDSE:skg, top right panel) of streptokinase activity. (B) Clot formation and lysis parameters of suscep-
tible blood-derived PPP in the presence or absence of streptokinase activity. (C) Thromboelastogram of susceptible blood-derived PPP treated with rSkg in the absence (rSkg 
control, left panel) or presence (rSkg + ex-IgGs, right panel) of ex-IgGs. (D) Clot formation and lysis parameters of susceptible blood-derived PPP in the presence or absence 
of ex-IgGs. Values were calculated by pooling the results of 3 independent experiments on a single susceptible donor. Mean values are reported ± standard deviation. 
Significance was calculated using the unpaired t test (*, P < .05; ****, P < .001). Abbreviations: CFT, clot formation time; LI30, lysis index at 30 minutes; LI45, lysis index at 45 
minutes; ML, maximum lysis; ns, nonsignificant. rSkg, 3 U/mL final concentration; ex-IgGs, commercial pooled human intravenous Ig (10 g/mL final concentration).
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immunoglobulin ameliorated the outcome of the infection in 
an NF mouse model.
In recent years, the emergence of SDSE-associated invasive 
infections has been reported [2, 3]. Invasive infections caused 
by streptococci progress very rapidly, and the lethality asso-
ciated with such infections, despite state of the art therapy, 
remains elevated. To dissect the pathophysiology of severe 
SDSE-associated NF, we started from the clinical observation 
of lack of fibrin barriers containing acute inflammation areas 
in the patient’s histology. Although some bacteria, such as 
Staphyloccoccus aureus, counteract containment and fibrin wall 
formation via the virulence factor staphylothrombin, strepto-
cocci produce streptokinase, efficiently lysing clots [21]. We 
speculated that the clinical severity observed in this specific pa-
tient was, at least in part, due to the dissolution of fibrin barri-
ers, promoting bacterial spread along the fascia. In a first step, 
we examined the interplay between the bacterial VF streptoki-
nase and function-blocking host antibodies. We found that the 
patient’s blood and blood from a small subset of healthy vol-
unteers lacked the capacity of blocking clot lysis triggered by 
SDSE NF-isolate supernatants. On the contrary, blood drawn 
from most healthy volunteers tested was resistant to the SDSE 
NF-isolate supernatants-mediated clot lysis. This was a first in-
dication that the patient, and the small subset of healthy donors, 
might lack a factor able to block an important VF secreted by 
SDSE and thus be at risk for severe disease.
In a second step, we analyzed the characteristics of the patho-
gen by assessing the activity of streptococcal VFs, other than 
streptokinase, reported to contribute to disease severity in 
streptococcal NF. The pore-forming toxin SLO binds to cho-
lesterol molecules present on the eukaryotic cell membrane to 
create pores and cause cell lysis [22]. The SLO was expressed 
at a similar level in the SDSE and GAS NF-isolates. The activ-
ity of SpeB [23], which degrades and inhibits many different 
substrates including human immunoglobulin [24], the comple-
ment factor C3 [25–27], and GAS’ own VFs [15], was lacking in 
the SDSE NF-isolate. Despite the importance of DNase in GAS 
virulence [12, 28], we found the SDSE NF-isolate to be clinically 
highly virulent despite the absence of DNase activity. Similarly, 
the IL-8-cleaving enzyme SpyCEP, interfering with host neu-
trophil recruitment [10], was absent in the SDSE NF-isolate as 
was the case for hyaluronic acid capsule expression, import-
ant in GAS for bacterial adherence [29]. In contrast to GAS, 
the SDSE NF-isolate expressed high levels of streptokinase. 
Streptokinase is an enzyme involved in the binding and activa-
tion of plasminogen to plasmin, promoting fibrinolysis. During 
infection, however, streptococci counteract containment of 
the infection normally mediated by host’s formation of fibrin 
deposits around the site of infection. Enzymatic fibrinolysis is 
not restricted to Streptococcus bacterial species but also present 
in fungal pathogens such as Candida [30]. Because of strepto-









































































Figure 4. Blockage or absence of streptokinase activity leads to a better clinical outcome. (A) C57BL/6 wild‐type mice were infected subcutaneously with the Streptococcus 
dysgalactiae subspecies equisimilis (SDSE) necrotizing fasciitis (NF) isolate and treated or not treated with exogenous immunoglobulin (ex-IgGs). (B) C57BL/6 wild‐type mice 
were infected subcutaneously with the SDSE NF-isolate or the insertional mutant devoid of streptokinase activity (SDSE:skg). Three days postinfection, mice were euthanized 
and bacteria in the skin was enumerated. Lesions size at the site of infection was measured 3 days postinfection. (A–B) Data were pooled from 3 and 2 independent experi-
ments, respectively, using 4 and 5 mice/group, respectively, and presented as mean ± standard error of the mean. Significance was calculated using the unpaired t test (*, P 
< .05; **, P < .01). Abbreviations: cfu, colony-forming units; ns, nonsignificant.
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the bacterial surface degrading key host antimicrobial peptides 
such as LL-37 [21, 31]. The importance of streptokinase activity 
for virulence was previously shown in a murine GAS model [21, 
32] as well as that the variability of streptokinase-mediated plas-
minogen activation influences virulence and disease outcome 
[32–34]. We reasoned that, given the absence of fibrin barriers 
surrounding inflamed areas in the patient’s tissue and given the 
prominent streptokinase production in the SDSE NF-isolate, 
the lack of streptokinase-blocking antibodies in the host would 
result in bacterial spreading and ultimately the extreme clinical 
manifestation observed.
In accordance, depletion of en-IgGs from resistant blood 
phenotype resulted in blood clot lysis mediated by SDSE super-
natants, and addition of ex-IgGs to susceptible blood phenotype 
resulted in blockage of clot lysis ex vivo. As a proof of principle, 
ex-IgGs efficiently blocked blood clot lysis mediated by rSkg.
Consistently, in a NF mouse-model, the lesions caused by 
the SDSE NF-isolate were significantly reduced by treatment 
with ex-IgGs. Due to the lack of prospective randomized clin-
ical trials, treatment of NF with ex-IgGs is still discussed con-
troversially. However, a recent observational study [8] showed 
that treatment with ex-IgGs results in clinical benefit in STSS 
outcome, corroborating previous work showing that strepto-
coccal toxins are blocked by ex-IgGs in cell culture [35–38]. 
Our case and the associated mechanistic studies provide the-
oretical support for a therapeutic role of ex-IgGs in NF caused 
by SDSE. The ex-IgGs efficiently blocked fibrinolysis, as shown 
ex vivo in PPP, by blocking streptokinase activity. Moreover, 
lack of streptokinase or blockage by ex-IgGs resulted in in vivo 
benefits in our murine NF model. Nevertheless, our index pa-
tient succumbed, despite receiving ex-IgGs in addition to sur-
gery and all recommended therapeutic options, including cell 
wall active antibiotics and bacterial protein synthesis inhibitors. 
However, the patient presented at an extremely advanced stage 
of disease and in addition had a high number of comorbidi-
ties. The potential selection bias in which patients who are the 
most ill receive therapy with ex-IgGs may underline some of 
the controversial data found on ex-IgG efficacy in NF patients 
[7, 39–42]. Consistent with a role of streptokinase activity in 
bacterial spreading, we observed that in the NF mouse model, 
wound lesions were significantly larger in animals infected with 
the streptokinase-expressing SDSE NF-isolate compared with 
its streptokinase-deficient counterpart SDSE:skg.
CONCLUSIONS
We conclude that concomitant expression of high levels of strepto-
kinase by the SDSE NF-isolate and the lack of streptokinase-block-
ing antibodies in the patient strongly contributed to disease 
severity, stressing the importance of the interaction between host 
and bacterial pathogen. Based on our human ex vivo and in vivo 
murine studies, we conclude that infused ex-IgGs might compen-
sate for the lack of streptokinase-blocking antibodies. Therefore, 
the use of ex-IgGs as an adjunctive therapy to antibiotics and sur-
gical debridement merits further investigation.
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